Sympathoinhibitory Response to Clonidine Is Blunted in Patients With Heart Failure

Hypertension

Volumn 30, Issue 3, 1997, Pages 392-397

  Lang, Chim C ^a   Stein, C Michael ^a   Nelson, Richard A ^a   He, Huai B ^a   Belas, Frank J ^a   Blair, Ian A ^a   Wood, Margaret ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; NITRATE; NORADRENALIN; TRITIUM;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CATECHOLAMINE METABOLISM; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART FAILURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL;

ADRENERGIC ALPHA-AGONISTS; AGED; CLONIDINE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; KINETICS; NEURAL INHIBITION; NOREPINEPHRINE; OSMOLAR CONCENTRATION; REFERENCE VALUES; SYMPATHETIC NERVOUS SYSTEM;

EID: 0030798681     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.30.3.392     Document Type: Article

References (46)

1. Chidsey CA, Braunwald E, Morrow AG. Catecholamine excretion and cardiac stress of norepinephrine in congestive heart failure. Am J Med. 1965;39:442-451.
2. Levine TB, Francis GS, Goldsmith SR, Simon A, Cohn JN. Activity of the sympathetic nervous system and renin angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 1982;49:1659-1666.
3. Davis D, Baily R, Zelis R. Abnormalities in systemic norepinephrine kinetics in human congestive heart failure. Am J Physiol. 1988;254:E760-E766.
4. Haskings GJ, Esler MD, Jennings GL, Burton D, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-621.
5. Leimbach WN, Wallin G, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneuronal recordings for increased central sympathetic outflow in patients with heart failure. Circulation. 1986;73:913-919.
6. Bristow MR. The adrenergic nervous system in heart failure. N Engl J Med. 1984;11:850-851.
7. Arnold SB, Williams RL, Ports TA, Baughman RA, Benet LZ, Parmley WW, Chatterjee K. Attenuation of prazosin's effect on cardiac output in chronic heart failure. Ann Intern Med. 1979;91:345-349.
8. Packer M, Miller J, Gorlin R, Herman MV. Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation. 1979;59:531-539.
9. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effects of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med. 1986;314:1547-1552.
10. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol. 1993;71:12C-22C.
11. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.
12. CIBIS Investigators and Committee. A randomized trial of B-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;20:1765-1773.
13. Lambert GW, Kaye DM, Lefkovits J, Jennings GL, Turner AG, Cox HS, Esler MD. Increased central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients. Circulation. 1995;92:1813-1818.
14. Manolis AJ, Olympios C, Sifaki M, Handanis S, Bresanahan M, Gavras I, Gavras H. Suppressing sympathetic activation in congestive heart failure: a new therapeutic strategy. Hypertension. 1995;26:719-724.
15. Isaac L. Clonidine in the central nervous system: site of mechanism of hypotensive action. J Cardiovasc Pharmacol. 1980;2(suppl 1):S5-S19.
16. Sharma JN, Sandrew B, Wang SC. CNS site of clonidine induced hypotension: a micro iontophoretic study of cardiovascular neurons. Brain Res. 1978;151:127-133.
17. Svensson TH, Bunney BS, Aghajanian GK. Inhibition of both nor-adrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res. 1975;92:291-306.
18. Dontenwill M, Tibirica E, Greney H, Bennai F, Feldman J, Stutzmann J, Bricca G, Belcourt A, Bousquet P. Role of imidazoline receptors in cardiovascular regulation. Am J Cardiol. 1994;74:27-41.
19. Kobinger W. Central alpha-adrenergic system as targets for hypotensive drugs. Rev Physiol Biochem Pharmacol. 1978;81:39-100.
20. 1 receptor downregulation in heart failure. Circ Res. 1986;59:297-309.
21. Lefkowitz RJ, Caron MG, Stiles GL. Mechanisms of membrane-receptor regulation: biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors. N Engl J Med. 1984;310:1570-1578.
22. Leier CV, Binkley PF, Cody RJ. alpha-Adrenergic component of the sympathetic nervous system in congestive heart failure. Circulation. 1990;82(suppl I):I-68-I-76.
23. Esler M, Jennings G, Korner P, Blombery P, Sacharias N, Leonard P. Measurement of total and organ-specific norepinephrine kinetics in humans. Am J Physiol. 1984;247:E21-E28.
24. Stein CM, Deegan R, He HB, Wood AJJ. Beta adrenergic receptor mediated release of norepinephrine in the human forearm. Clin Pharmacol Ther. 1993;54:58-64.
25. Lang CC, Stein CM, He HB, Belas FJ, Blair IA, Wood M, Wood AJJ. Blunted blood pressure response to central sympathoinhibition in normotensive blacks: increased importance of non-sympathetic factors in blood pressure maintenance in blacks. Hypertension. In press.
26. He HB, Deegan RJ, Wood M, Wood AJJ. Optimization of HPLC assay for catecholamines: determination of ideal mobile phase composition and elimination of species dependent differences in extraction recovery of DHBA. J Chromatogr. 1992;574:213-218.
27. Murray S, Davies DS. Bis(trifluoromethyl)aryl derivatives for drug analysis by gas chromatography electron capture negative ion chemical ionization mass spectrometry. Biomed Mass Spectrom. 1984;11:435-440.
28. Giles TD, Iteld BJ, Mautner RK, Rognoni PA, Dillenkoffer RL. Short-term effects of intravenous clonidine in congestive heart failure. Clin Pharmacol Ther. 1981;30:724-728.
29. Giles TD, Thomas MG, Quiroz AC, Rice JC, Plauche W, Sander GE. Acute and short-term effects of clonidine in heart failure. Angiology. 1987;38:537-548.
30. Hermiller JB, Magorien RD, Leithe ME, Unverferth DV, Leier CV. Clonidine in congestive heart failure: a vasodilator with negative inotropic effect. Am J Cardiol. 1983;51:791-795.
31. Giles TD. Clonidine and heart failure. Hypertension. 1996;27:1187-1188. Letter.
32. Starke K. Regulation of catecholamine release: receptor mediated feedback control in peripheral and central neurons. In: Usdin E, Snyder SH, eds. Frontiers in Catecholamine Research. Oxford, UK: Pergamon Press; 1973:561-565.
33. Langer SZ. Presynaptic regulation of the release of catecholamines. Pharmacol Rev. 1981;32:337-362.
34. 2 -receptor mediated vasoconstriction in patients with congestive heart failure. Circulation. 1989;80:1660-1667.
35. Parker JD, Newton GE, Landzberg JS, Floras JS, Colucci WS. Functional significance of presynaptic alpha-adrenergic receptors in failing and nonfailing human left ventricle. Circulation. 1995;92:1793-1800.
36. Kooner JS, Birch R, Frankel H, Peart WS, Mathias CJ. Hemodynamic and neurohormonal effects of clonidine in patients with preganglionic and postganglionic sympathetic lesion: evidence for a central sympatholytic action. Circulation. 1991;84:75-83.
37. Bristow MR, Minobe W, Rasmussen R, Hershberger RB, Hoffman BB. Alpha-1 adrenergic receptors in the non-failing and failing heart. J Pharmacol Exp Ther. 1988;247:1039-1045.
38. 2) adrenoceptors in chronic congestive heart failure. Am J Cardiol. 1983;52:101-105.
39. Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev. 1990;70:963-985.
40. Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med. 1971;285:877-883.
41. Thames MD, Kinugawa T, Smith ML, Dibner-Dunlap ME. Abnormalities of baroreflex control in heart failure. J Am Coll Cardiol. 1993;22(suppl A):56A-60A.
42. Sole MJ, Benedict CR, Versteeg DHG, De Kloet ER. Digoxin therapy partially restores cardiac catecholamine and brain serotonin metabolism in congestive heart failure. J Mol Cell Cardiol. 1985;17:1055-1063.
43. Cohn JN. Abnormalities of peripheral sympathetic nervous system control in congestive heart failure. Circulation. 1990;82(suppl I):I-59-I-67.
44. Kubo T, Misu Y. Pharmacological characterization of the alpha-adrenoceptors responsible for a decrease of blood pressure in the nucleus tractus solitarii of the rat. Naunyn Schmiedebergs Arch Pharmacol. 1981;317:120-125.
45. Lang CC, Rayos GH, Chomsky DB, Wood AJJ, Wilson JR. Effect of sympathoinhibition on exercise performance in patients with heart failure. Circulation. In press.
46. Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol. 1993;22(suppl A):72A-84A.